Toxicity studies

Test Methods and Aim of Study	Results			Conclusion
	Body weight	**Necropsy**	**General evaluation**	
Acute Oral Toxicity To provide information on health hazards likely to arise from a short-term exposure to Stalosan® F by the oral route.	Gained body weight	No gross abnormalities were noted for any of the animals.	All animals survived and appeared active and healthy. There were no signs of gross toxicity, dermal irritation, adverse pharmacologic effects or abnormal behaviour.	The acute oral LD50 of Stalosan F is greater than 5,000 mg/kg of body weight.
Acute Dermal Toxicity Study To provide information on health hazards likely to arise from a short-term exposure to Stalosan® F by the dermal route.	Gained body weight	No gross abnormalities were noted for any of the animals.	All animals survived and appeared active and healthy. There were no signs of gross toxicity, dermal irritation, adverse pharmacologic effects or abnormal behaviour.	The single dose acute dermal LD50 of Stalosan F is greater than 5,000 mg/kg of body weight.
Acute Inhalation Toxicity Study To provide information on health hazards likely to arise from a short-term exposure to Stalosan® F by the inhalation route.	Gained body weight	No gross abnormalities were noted for any of the animals.	All animals survived and appeared active and healthy. There were no signs of gross toxicity, dermal irritation, adverse pharmacologic effects or abnormal behaviour.	The single dose acute dermal LD50 of Stalosan F is greater than 5,000 mg/kg of body weight.
Primary Eye Irritation Study To provide information on the irritation likely to arise from an instillation of Stalosan® F into the eye.	Gained body weight	No gross abnormalities were noted for any of the animals.	All animals survived and appeared active and healthy. There were no signs of gross toxicity, dermal irritation, adverse pharmacologic effects or abnormal behaviour.	Stalosan F is classified as mildly irritating to the eye.
Primary Skin Irritation Study To provide information on the skin irritation likely to arise from a single topical exposure to Stalosan® F.	Gained body weight	Not relevant	All animals survived and appeared active and healthy. There were no signs of gross toxicity, dermal irritation, adverse pharmacologic effects or abnormal behaviour.	Stalosan F is classified as non-irritating to the skin.
Dermal Sensitization Study To determine the potential for Stalosan® F to elicit a skin sensitization reaction.	Gained body weight	Not relevant	All animals survived and appeared active and healthy. There were no signs of gross toxicity, dermal irritation, adverse pharmacologic effects or abnormal behaviour.	Stalosan F is not considered to be a contact sensitizer.